Hepatitis B News and Research

Latest Hepatitis B News and Research

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (acetylcysteine) Injection to treat patients with non-acetaminophen induced acute liver failure.

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Gene variant linked to liver cirrhosis in Caucasians

A new study by German researchers found that a variation in the PNPLA3 (adiponutrin) gene was associated with cirrhosis of the liver and elevated transaminase (liver enzyme) levels in alcoholic Caucasians. The risk of cirrhosis in alcoholics in the genetic high risk group might be as high as 25 to 50%. Full findings are published in the January 2011 issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

16 Dec 2010

Gene variation linked to liver cirrhosis in alcoholic caucasians

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Researchers introduce new class of drugs for HCV patients

To improve the care for individuals infected with the hepatitis C virus, a major health problem and a leading cause of chronic liver disease around the world, nearly 200 international hepatitis experts have taken an important step in escalating the introduction of a new class of targeted therapies for HCV – direct-acting antivirals.

15 Dec 2010

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.

15 Dec 2010

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

14 Dec 2010

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.

14 Dec 2010

Biostar provides update on preliminary sales for October and November 2010

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today provided an update on preliminary sales for October and November 2010.

13 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

AiCuris announces completion of AIC316 Phase II genital herpes trial

The trial has been completed two months earlier than planned. Indeed, in the later stages of the trial, enrolment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.

8 Dec 2010

Novel therapy against hepatitis C disease

University of Maryland School of Pharmacy researchers have developed a mathematical model for choosing an appropriate dosage of the hepatitis medications for individual patients. The work helps explain why African American patients tend to not respond as well to the drugs as other patients.

8 Dec 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Gene variant linked to liver cirrhosis in Caucasians

Gene variation linked to liver cirrhosis in alcoholic caucasians

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Researchers introduce new class of drugs for HCV patients

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Biostar provides update on preliminary sales for October and November 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

AiCuris announces completion of AIC316 Phase II genital herpes trial

Novel therapy against hepatitis C disease

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis B News and Research

Latest Hepatitis B News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in